Quick Answer
Enovix Corp reported Research And Development Expense of $110.33 million for the year ending 2025.
- Enovix Corp showed a decrease of -11.4% in Research And Development Expense from 2024 to 2025.
- This data is from Enovix Corp's annual report (Form 10-K), filed with the SEC on February 25, 2026.
- XBRL data for this metric is available from 2020 to 2025 (6 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q3 2020: $3.81 million | Q1 2021: $5.59 million | Q2 2021: $9.52 million | Q3 2021: $10.30 million | Q1 2022: $12.73 million | Q2 2022: $15.83 million | Q3 2022: $13.95 million | Q1 2023: $23.75 million | Q2 2023: $16.55 million | Q3 2023: $13.51 million | Q1 2024: $48.79 million | Q2 2024: $29.07 million | Q3 2024: $24.22 million | Q1 2025: $25.93 million | Q2 2025: $28.15 million | Q3 2025: $28.18 million.
- Over the full 6 years of available data (2020 to 2025), Enovix Corp's Research And Development Expense has grown by 664.0%.
- Historical annual values: Fiscal year 2025: $110.33 million | Fiscal year 2024: $124.51 million | Fiscal year 2023: $88.39 million | Fiscal year 2022: $58.05 million | Fiscal year 2021: $37.85 million | Fiscal year 2020: $14.44 million.
- Data sourced from SEC EDGAR public filings as of August 5, 2026.
Last verified: